Alkem Laboratories' Q4 FY 2025-26 Quarterly Results

Result Summary

• Alkem Laboratories Ltd reported a 2.0% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 15.6%.
• Its expenses for the quarter were up by 6.6% QoQ and 12.2% YoY.
• The net profit decreased 61.5% QoQ and decreased 22.1% YoY.
• The earnings per share (EPS) of Alkem Laboratories Ltd stood at 19.77 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Alkem Laboratories Ltd is a leading pharmaceutical company in India, known for manufacturing and marketing a broad range of pharmaceutical formulations and nutraceutical products. The company operates across multiple therapeutic segments, including anti-infectives, gastrointestinal, pain management, and vitamins/minerals/nutrients. Alkem Laboratories has a significant presence in both domestic and international markets, with a strong emphasis on research and development to innovate and improve its product offerings. The company is recognized for its commitment to quality and compliance with industry standards. Recent developments or specific major events related to the company are not provided in the data.

Revenue

In the fourth quarter of the fiscal year 2026 (Q4FY26), Alkem Laboratories Ltd reported a total income of ₹3803.39 crores. This represents a slight decrease of 2.0% compared to the previous quarter (Q3FY26), where the total income was ₹3879.92 crores. However, when compared to the same quarter in the previous year (Q4FY25), there was a notable increase of 15.6% from ₹3289.71 crores. This year-over-year growth indicates a significant improvement in revenue generation over the twelve-month period.

Profitability

For Q4FY26, Alkem Laboratories reported a profit before tax of ₹422.85 crores, which marks a decrease of 45.9% from the previous quarter's profit before tax of ₹781.20 crores. Year-over-year, there was a modest increase of 6.7% when compared to ₹396.34 crores in Q4FY25. The tax expense for Q4FY26 was ₹171.17 crores, reflecting a quarter-over-quarter increase of 34.1% from ₹127.67 crores in Q3FY26 and a substantial year-over-year increase of 133.4% from ₹73.33 crores in Q4FY25. Consequently, the profit after tax for Q4FY26 was ₹251.11 crores, which is a significant decrease of 61.5% from the previous quarter and a decline of 22.1% from the same quarter in the previous year. Earnings per share for Q4FY26 stood at ₹19.77, experiencing a decrease of 62.8% quarter-over-quarter and 22.7% year-over-year.

Operating Metrics

The total expenses of Alkem Laboratories for Q4FY26 amounted to ₹3245.57 crores, representing a quarter-over-quarter increase of 6.6% from ₹3045.93 crores in Q3FY26 and a year-over-year rise of 12.2% from ₹2893.37 crores in Q4FY25. The increase in expenses over both periods highlights a trend of rising costs. The financial data does not provide specific details on operating metrics such as P/E ratio, debt-to-equity ratio, or current ratio. These metrics are essential for a more detailed analysis of the company's operational efficiency and financial health. However, the available data on total income, expenses, and profitability forms the basis for understanding the company's operational performance during the reported period.